Cargando…
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review
Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
by the American College of Cardiology Foundation. Published by Elsevier.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504484/ https://www.ncbi.nlm.nih.gov/pubmed/34649702 http://dx.doi.org/10.1016/j.jacc.2021.08.021 |
| _version_ | 1784581332815314944 |
|---|---|
| author | Talasaz, Azita H. Sadeghipour, Parham Aghakouchakzadeh, Maryam Dreyfus, Isaac Kakavand, Hessam Ariannejad, Hamid Gupta, Aakriti Madhavan, Mahesh V. Van Tassell, Benjamin W. Jimenez, David Monreal, Manuel Vaduganathan, Muthiah Fanikos, John Dixon, Dave L. Piazza, Gregory Parikh, Sahil A. Bhatt, Deepak L. Lip, Gregory Y.H. Stone, Gregg W. Krumholz, Harlan M. Libby, Peter Goldhaber, Samuel Z. Bikdeli, Behnood |
| author_facet | Talasaz, Azita H. Sadeghipour, Parham Aghakouchakzadeh, Maryam Dreyfus, Isaac Kakavand, Hessam Ariannejad, Hamid Gupta, Aakriti Madhavan, Mahesh V. Van Tassell, Benjamin W. Jimenez, David Monreal, Manuel Vaduganathan, Muthiah Fanikos, John Dixon, Dave L. Piazza, Gregory Parikh, Sahil A. Bhatt, Deepak L. Lip, Gregory Y.H. Stone, Gregg W. Krumholz, Harlan M. Libby, Peter Goldhaber, Samuel Z. Bikdeli, Behnood |
| author_sort | Talasaz, Azita H. |
| collection | PubMed |
| description | Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. |
| format | Online Article Text |
| id | pubmed-8504484 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | by the American College of Cardiology Foundation. Published by Elsevier. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85044842021-10-12 Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review Talasaz, Azita H. Sadeghipour, Parham Aghakouchakzadeh, Maryam Dreyfus, Isaac Kakavand, Hessam Ariannejad, Hamid Gupta, Aakriti Madhavan, Mahesh V. Van Tassell, Benjamin W. Jimenez, David Monreal, Manuel Vaduganathan, Muthiah Fanikos, John Dixon, Dave L. Piazza, Gregory Parikh, Sahil A. Bhatt, Deepak L. Lip, Gregory Y.H. Stone, Gregg W. Krumholz, Harlan M. Libby, Peter Goldhaber, Samuel Z. Bikdeli, Behnood J Am Coll Cardiol The Present and Future Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. by the American College of Cardiology Foundation. Published by Elsevier. 2021-10-19 2021-10-11 /pmc/articles/PMC8504484/ /pubmed/34649702 http://dx.doi.org/10.1016/j.jacc.2021.08.021 Text en © 2021 by the American College of Cardiology Foundation. Published by Elsevier. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | The Present and Future Talasaz, Azita H. Sadeghipour, Parham Aghakouchakzadeh, Maryam Dreyfus, Isaac Kakavand, Hessam Ariannejad, Hamid Gupta, Aakriti Madhavan, Mahesh V. Van Tassell, Benjamin W. Jimenez, David Monreal, Manuel Vaduganathan, Muthiah Fanikos, John Dixon, Dave L. Piazza, Gregory Parikh, Sahil A. Bhatt, Deepak L. Lip, Gregory Y.H. Stone, Gregg W. Krumholz, Harlan M. Libby, Peter Goldhaber, Samuel Z. Bikdeli, Behnood Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review |
| title | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review |
| title_full | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review |
| title_fullStr | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review |
| title_full_unstemmed | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review |
| title_short | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review |
| title_sort | investigating lipid-modulating agents for prevention or treatment of covid-19: jacc state-of-the-art review |
| topic | The Present and Future |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504484/ https://www.ncbi.nlm.nih.gov/pubmed/34649702 http://dx.doi.org/10.1016/j.jacc.2021.08.021 |
| work_keys_str_mv | AT talasazazitah investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT sadeghipourparham investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT aghakouchakzadehmaryam investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT dreyfusisaac investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT kakavandhessam investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT ariannejadhamid investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT guptaaakriti investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT madhavanmaheshv investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT vantassellbenjaminw investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT jimenezdavid investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT monrealmanuel investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT vaduganathanmuthiah investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT fanikosjohn investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT dixondavel investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT piazzagregory investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT parikhsahila investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT bhattdeepakl investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT lipgregoryyh investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT stonegreggw investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT krumholzharlanm investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT libbypeter investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT goldhabersamuelz investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview AT bikdelibehnood investigatinglipidmodulatingagentsforpreventionortreatmentofcovid19jaccstateoftheartreview |